Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10164)	1/27/2004 2:53:42 PM
From: Icebrg	Respond to of 52153

>>What does that oncology blog you found (I've lost the url) suggest for MDS?>> Dr. Cancerblogger is available at oncologynews.info Nothing much about MDS. There is a note from last year's ASH conference. LEUKEMIA 12-10-2003 Since thalidomide has been shown to improve the red blood count in myelodysplasia, it has been hoped that the more potent (and less toxic) CC5013 (Revimid) would be as or more effective. Indeed, the latest data from this year's ASH meeting suggests that it is effective in 64% in improving red blood counts, even producing normalization of abnormal bone marrow karyotype and decreasing blast percentage, which is something rarely seen with thalidomide. It is interesting that the side-effects seen were a dose-dependent reduction in platelets, since the scuttlebutt that I've heard is that in cases of 5q- syndrome, one can see improvement in the platelet count. I tried to get in contact with the guy but, his email address had passed its use-before date. Erik